论文部分内容阅读
目的探讨乳腺癌患者LAPTM4B在肿瘤组织中的表达水平,并评估其在乳腺癌患者预后预测中的地位。方法采用组织芯片(tissue array)技术及免疫组化法检测210例乳腺癌患者肿瘤组织中LAPTM4B表达水平,并收集临床病理资料及随访。结果 LAPTM4B表达水平与乳腺癌患者家族史有关,统计学分析差别有统计学意义(P<0.05),与其他临床病理因素(分子分型、临床分期等)相关性分析无统计学意义。LAPTM4B蛋白高水平表达的乳腺癌患者的预后较差,与LAPTM4B蛋白低表达的乳腺癌患者比较差别有统计学意义(P=0.01)。结论 LAPTM4B蛋白表达水平与遗传因素有关,检测该蛋白表达水平可预测乳腺癌患者的预后。
Objective To investigate the expression of LAPTM4B in breast cancer patients and to evaluate its role in the prediction of prognosis of patients with breast cancer. Methods Tissue tissue technology and immunohistochemistry were used to detect the expression of LAPTM4B in 210 cases of breast cancer and to collect clinical and pathological data and follow-up. Results The expression level of LAPTM4B was related to the family history of breast cancer patients. There was a statistically significant difference (P <0.05) between the expression of LAPTM4B and other clinicopathological factors (molecular typing, clinical stage, etc.). The prognosis of breast cancer patients with high expression of LAPTM4B protein is poor, which is statistically different from that of patients with low expression of LAPTM4B protein (P = 0.01). Conclusion The expression level of LAPTM4B protein is related to genetic factors. Detecting the expression level of LAPTM4B protein can predict the prognosis of breast cancer patients.